News for Catalyst Pharmaceuticals, Inc. (CPRX)

Summary Catalyst Pharmaceuticals Inc (CPRX), a commercial-stage biopharmaceutical company specializing in the development and commercialization of treatments fo

The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET CORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalys

Transaction Overview On July 1, 2025, JW Asset Management, LLC (Trades, Portfolio) executed a strategic transaction involving Establishment Labs Holdings Inc (E

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

On May 30, 2025, Richard Daly, President and Chief Executive Officer of Catalyst Pharmaceuticals Inc (CPRX), sold 70,000 shares of the company, according to a S

In a recent regulatory filing, Catalyst Pharmaceuticals (CPRX) revealed that its president and CEO, Richard Daly, acquired 70,000 shares of the company's stock.

Summary Catalyst Pharmaceuticals Inc (CPRX) has announced the appointment of Dr. William T. Andrews as the new Chief Medical Officer, effective June 2, 2025. Dr

Catalyst Pharmaceuticals (CPRX) has appointed Dr. William Andrews as its new Chief Medical Officer. Dr. Andrews will report to President and CEO Richard Daly an

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Catalyst Pharmace

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NCPRX.OQ - Catalyst Pharmaceuticals IncQ1 2025 Catalyst Pharmaceuticals Inc Earnings CallMay 08

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsMichael Kalb - Executive Vice...

Catalyst Pharmaceuticals (CPRX) Q1 earnings report is set for May 7. Analysts anticipate $0.53 EPS (+39.5% Y/Y) and $131.13M revenue.

On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Catalyst Pharmaceuticals Inc (CPRX). The firm reduced its ho

CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (”œCatalyst” or ”œCompany”) ( CPRX), a commercial-stage biopharmac

**media[608305]**

We recently published a list of 11 Stocks with Consistent Growth to Buy Now. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands against stocks with consistent growth to buy now. The market is clouded by friction between trading partners. But even at these uncertain times, one […]

CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ('Catalyst' or 'Company') (Nasdaq: CPRX), a commercial-st...

We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands against other best Russell 2000 stocks to buy according to Wall Street analysts. Since President Trump announced new tariffs, the […]